AIM: To evaluate the efficacy of ursodeoxycholic acid(UDCA) as a chemotherapeutic agent for the treatment of hepatocellular carcinoma(HCC).METHODS: BALB/c nude mice were randomized into four groups 24 h before subcutaneous injection of hepatocarcinoma BEL7402 cells suspended in phosphate buffered saline(PBS) into the right flank. The control group(n = 10) was fed a standard diet while treatment groups(n = 10 each) were fed a standard daily diet supplemented with different concentrations of UDCA(30,50 and 70 mg/kg per day) for 21 d. Tumor growth was measured once each week,and tumor volume(V) was calculated with the following equation: V =(L × W2) × 0.52,where L is the length and W is the width of the xenograft. After 21 d,mice were killed under ether anesthesia,and tumors were excised and weighed. Apoptosis was evaluated through detection of DNA fragmentation with gel electrophoresis and the terminaldeoxynucleotidyl transferase-mediated d UTP-biotin nick end labeling(TUNEL) assay. Western blot analysis was performed to determine the expression of apoptosisrelated proteins BAX,BCL2,APAF1,cleaved caspase-9,and cleaved caspase-3.RESULTS: UDCA suppressed tumor growth relative to controls. The mean tumor volumes were the following: control,1090 ± 89 mm3; 30 mg/kg per day,612 ± 46 mm3; 50 mg/kg per day,563 ± 38 mm3; and 70 mg/kg per day,221 ± 26 mm3. Decreased tumor volumes reached statistical significance relative to control xenografts(30 mg/kg per day,P < 0.05; 50 mg/kg per day,P < 0.05; 70 mg/kg per day,P < 0.01). Increasing concentrations of UDCA led to increased DNA fragmentation observed on gel electrophoresis and in the TUNEL assay(control,1.6% ± 0.3%; 30 mg/kg per day,2.9% ± 0.5%; 50 mg/kg per day,3.15% ± 0.7%,and 70 mg/kg per day,4.86% ± 0.9%). Western blot analysis revealed increased expression of BAX,APAF1,cleaved-caspase-9 and cleaved-caspase-3 proteins,which induce apoptosis,but decreased expression of BCL2 protein,which is an inhibitor of apoptosis,following administration of UDCA. CONCLUSION: UDCA suppresses growth of BEL7402 hepatocellular carcinoma cells in vivo,in part through apoptosis induction,and is thus a candidate for therapeutic treatment of HCC. AIM: To evaluate the efficacy of ursodeoxycholic acid (UDCA) as a chemotherapeutic agent for the treatment of hepatocellular carcinoma (HCC). METHODS: BALB / c nude mice were randomized into four groups 24 h before subcutaneous injection of hepatocarcinoma BEL7402 cells suspended in phosphate The control group (n = 10) was fed a standard diet while treatment groups (n = 10 each) were fed a standard daily diet supplemented with different concentrations of UDCA (30, 50 and 70 mg / kg per day) for 21 d. Tumor growth was measured once each week, and tumor volume (V) was calculated with the following equation: V = (L × W2) × 0.52, where L is the length and W is the width of the xenograft. After 21 d, mice were killed under ether anesthesia, and tumors were excised and weighed. Apoptosis was evaluated through detection of DNA fragmentation with gel electrophoresis and the terminal deoxynucleotidyl transferase-mediated d UTP-biotin nick end labeling (TUNEL) assay stern blot analysis was performed to determine the expression of apoptosis associated proteins BAX, BCL2, APAF1, cleaved caspase-9, and cleaved caspase-3.RESULTS: UDCA suppressed tumor growth relative to controls. The mean tumor volumes were the following: control, 1090 ± 89 mm3; 30 mg / kg per day, 612 ± 46 mm3; 50 mg / kg per day, 563 ± 38 mm3; and 70 mg / kg per day, 221 ± 26 mm3. Decreased tumor volumes reached statistical significance relative to control P <0.05; 50 mg / kg per day, P <0.05; 70 mg / kg per day, P <0.01) Increasing concentrations of UDCA led to increased DNA fragmentation observed on gel electrophoresis and in the TUNEL assay (control, 1.6% ± 0.3%; 30 mg / kg per day, 2.9% ± 0.5%; 50 mg / kg per day, 3.15% ± 0.7%, and 70 mg / kg per day, 4.86% ± 0.9%). Western blot analysis revealed increased expression of BAX, APAF1, cleaved-caspase-9 and cleaved-caspase-3 proteins, which induce apoptosis, but decreased decreased of BCL2 protein, which is an inhibitor of apoptosis , followingadministration of UDCA. CONCLUSION: UDCA suppresses growth of BEL7402 hepatocellular carcinoma cells in vivo, in part through apoptosis induction, and therefore a candidate for therapeutic treatment of HCC.